CING logo

CING
Cingulate Inc

4,321
Mkt Cap
$66.98M
Volume
300,290.00
52W High
$11.89
52W Low
$3.20
PE Ratio
-1.32
CING Fundamentals
Price
$5.76
Prev Close
$5.96
Open
$5.97
50D MA
$6.77
Beta
0.55
Avg. Volume
690,231.40
EPS (Annual)
-$4.44
P/B
16.65
Rev/Employee
$0.00
$19.77
Loading...
Loading...
News
all
press releases
Ascendiant Capital Markets Has Lowered Expectations for Cingulate (NASDAQ:CING) Stock Price
Ascendiant Capital Markets cut their price objective on Cingulate from $58.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00
Roth Mkm decreased their price objective on Cingulate from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Monday...
MarketBeat·19d ago
News Placeholder
What's Going On With Cingulate Stock Today?
Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.read more...
Benzinga·22d ago
News Placeholder
Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS
Cingulate (NASDAQ:CING - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28...
MarketBeat·23d ago
News Placeholder
Cingulate (CING) Expected to Announce Earnings on Thursday
Cingulate (NASDAQ:CING) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-cingulate-inc-stock...
MarketBeat·24d ago
News Placeholder
Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst
The FDA has set May 31 as the PDUFA target date to decide on Cingulate’s ADHD drug CTx-1301.
Stocktwits·27d ago
News Placeholder
Cingulate (NASDAQ:CING) Trading Up 6.5% - Here's What Happened
Cingulate (NASDAQ:CING) Shares Up 6.5% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Cingulate (NASDAQ:CING) CEO Shane Schaffer Purchases 6,809 Shares
Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer acquired 6,809 shares of the company's stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost...
MarketBeat·2mo ago
News Placeholder
Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock
Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer purchased 6,809 shares of Cingulate stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average...
MarketBeat·2mo ago
News Placeholder
Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock
Cingulate Inc. (NASDAQ:CING - Get Free Report) Director Peter Werth acquired 19,455 shares of the company's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...
MarketBeat·2mo ago
<
1
2
...
>

Latest CING News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.